Infinity Announces Leadership Promotions

CAMBRIDGE, Mass., April 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals,
Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company,
today announced two leadership promotions: John J. Keilty to vice president,
information technology and informatics, and Joseph F. McPherson to vice
president, facilities and operations. These appointments facilitate the
advancement of Infinity's mission to discover, develop, and deliver to patients
important new medicines for the treatment of cancer, and reflect Infinity's
commitment to leadership development.

John J. Keilty, promoted to vice president, information technology and
informatics, is a member of the Company's executive leadership team and has been
a key figure in building Infinity's informatics and information technology
development functions since joining the company as one of its earliest employees
in early 2002. Mr. Keilty is responsible for information systems, software
development, structural biology, bioinformatics, and clinical informatics. Prior
to joining Infinity, Mr. Keilty was an early member of Millennium
Pharmaceuticals where he had a diversity of responsibilities, including sequence
analysis, genotyping, application development, and DNA sequencing. Mr. Keilty
received his B.A. in biology from Clark University.

"John has worked tirelessly and has introduced tremendous innovation in the
informatics arena to accelerate and support Infinity's mission to develop
important new medicines to treat patients with cancer," said Julian Adams,
Ph.D., president of research and development and chief scientific officer,
Infinity. "John has also played a critical role in shaping and enhancing
Infinity's core values and culture, and his enthusiasm and influence extends
into all aspects of how Infinity operates."

Joseph F. McPherson, promoted to vice president, facilities and operations,
joined Infinity at its inception in 2001 and has been instrumental in managing
the company's expanding laboratories and office space, health and safety
programs, and supply chain activities. Mr. McPherson joined Infinity with more
than twenty years of laboratory and facility operations and management
experience, and previously held positions at Applied Biotechnology, Inc.,
ImmuLogic Pharmaceutical, Inc., and Anadys Pharmaceuticals where he planned and
managed the construction of the company's office/manufacturing space and
relocations. Mr. McPherson received his B.S. in Biochemistry from the University
of Massachusetts in Amherst.

"As one of Infinity's first employees, Joe has been instrumental in developing
the fabric of our company," said Adelene Q. Perkins, president and chief
business officer, Infinity. "The breadth and depth of Joe's expertise, combined
with his energy and enthusiasm, has enabled him to make extraordinary
contributions to the company's success. He is a key leader in executing on our
growth strategy and I look forward to his future contributions."

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company seeking
to discover, develop, and deliver to patients best-in-class medicines for the
treatment of cancer and related conditions. Infinity combines proven scientific
expertise with a passion for developing novel small molecule drugs that target
emerging cancer pathways. Infinity's two most advanced programs in Hsp90
inhibition and Hedgehog signaling pathway inhibition are evidence of its
innovative approach to oncology drug discovery and development. For more
information on Infinity, please refer to the company's website at
http://www.infi.com.

-0-
CONTACT: Infinity Pharmaceuticals, Inc.
Monique Allaire
617-453-1105
Monique.Allaire@infi.com
http://www.infi.com